🔎 Trials Near Me

Home › Alzheimer's Disease › NCT05925621

Cognitive Neurology Unit Clinical Registry

RecruitingObservational study

Cognitive Neurology Unit's Anti-amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease Clinical Registry

Who can join

Ages 50 to 95 · All sexes

Full eligibility criteria
Inclusion Criteria:

* o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease

  * Patient has evidence of cognitive impairment on neuropsychological testing
  * Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement
  * Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease
  * Amyloid PET imaging positive
  * CSF p-Tau/Abeta42 ration \>0.023 and ABeta42 \< 1027\*\*
  * 3T MRI in past 6 months
  * Patient has a care partner
  * Patient under the care of an appropriate BI-Lahey amyloid clinic
  * Patient is on a stable medication regimen

Exclusion Criteria:

* o Recent stroke or suspected TIA in the past year

  * Pregnancy
  * Active autoimmune or immunological disease
  * Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives
  * Bleeding disorder with Plts \< 50,000 or INR \> 1.5
  * On warfarin, heparin, or DOAC
  * On dual antiplatelet therapy
  * Non Alzheimer disease cause of dementia/MCI
  * ApoE e4 homozygote

About the study

A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease

What is being tested

Sponsor: Beth Israel Deaconess Medical Center · Participants: 500 · Started: Jul 16, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT05925621

Locations in the U.S.

MassachusettsBeth Israel Deaconess Medical Center, Boston

Conditions

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.